CURRICULUM VITAE

Osobni podaci:

Ime: Prof. dr. sc. Eduard Vrdoljak

E-mail: eduard.vrdoljak@st.t-com.hr

Vrijeme i mjesto rođenja: Studeni 22, 1964, Livno, Bosna i Hercegovina

Državljanstvo: Hrvatsko

Bračni status: Oženjen, otac dvoje djece

Radna adresa:

Centar za Onkologiju i Radioterapiju

Klinički bolnički centar "Split"
Spinčićeva 1, 21000 Split, Hrvatska
Telefon: + 385 (0)21 556 129
Telefax: + 385 (0)21 556 460

Naobrazba:

 Medicinski fakultet Zagreb, Medicinski studij Split, Hrvatska, M.D.

 l989, Medicina.
 Medicinski fakultet Zagreb, PhD, doktorat znanosti, Onkologija, 1995.
 Medicinski fakultet Zagreb, KB Split, Centar za onkologiju i radioterapiju,
specijalizacija iz radioterapije i onkologije, 1995.

Postdoktorska naobrazba:

1990 – 1992 Project Investigator, Department of Experimental Radiotherapy,

University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA,
Dr. Philip Tofilon,
1997 Gostujući znanstvenik i promatrač, Department of Radiation Oncology i
Department of Experimental Radiation Oncology, University of Texas,
M.D. Anderson Cancer Center, Houston, TX, USA, Dr. James Cox i
Dr. Luka Milas.

Zaposlenja:

1
.
1992 – 1995 specijalizant iz radioterapije i onkologije, Centar za Onkologiju i
Radioterapiju, Klinička Bolnica "Split".
1995 – danas specijalist onkologije i radioterapije KBC Split
1995/1996 viši asistent u kumulativnom radnom odnosu na katedri za
radiologiju i opću kliničku onkologiju Medicinskog fakulteta u
Zagrebu za potrebe nastave u Splitu
1997/1998 Docent u kumulativnom radnom odnosu na katedri za radiologiju i
opću kliničku onkologiju Medicinskog fakulteta u Zagrebu za
potrebe nastave u Splitu
2002/2003 Izvanredni profesor na katedri za radiologiju i opću kliničku
onkologiju Medicinskog fakulteta u Zagrebu za potrebe nastave u
Splitu
2007/2008 Redoviti profesor na Medicinskom fakultetu u Splitu i Mostaru
2001/2002 Gostujući profesor na Medicinskom fakultetu u Mostaru
2003 – danas Savjetnik na Klinici za onkologiju KB Mostar
2007 – danas Predsjednik Jugoistočna Europska Grupa za Istraživanja na
Području Onkologije
2008 – danas Predsjednik Hrvatskog onkološkog društva

Članstvo u medicinskim organizacijama:

 European Association for Cancer Research

 European Society for Medical Oncology
 American Society of Clinical Oncology
 Hrvatsko onkološko društvo
 Gilbert H. Fletcher Society
 European Organization for Research and Treatment of Cancer
 Hrvatska udruga za promicanje kliničkih istraživanja u onkologiji
 Asian Gynaecology Oncology Group
 Jugoistočna Europska Grupa za Istraživanja na Području Onkologije

Nagrade:

 10th International Congress of Radiation ResearchYoung Scientist Traveler

Award, 1995.
 World Associaton of Croatian Physicians Fellowship Award 1995 (MD Anderson
Cancer Center, Houston, TX, USA, February and March 1996.
 Najbolji rad na 1. Hrvatskom onkološkom kongresu, Plitvice, 2001
 Nagrada Hrvatske akademije znanosti I umjetnosti za najviša znanstvena I
umjetnička dostignuća u Republici Hrvatskoj u području medicinskih znanosti
-2008

2
 Aktivnosti:

 Predsjednik Županijske lige protiv raka – Split (2003 -)

 Član Središnjeg etičkog povjerenstva Ministarstva zdravstva RH (2006 -)
 Član Povjerenstva za onkologiju Ministarstva Zdravstva RH (2003 -)
 Član Povjerenstva Ministarstva zdravstva i socijalne skrbi za definiranje
tehničkih karakteristika medicinske opreme
 Član Povjerenstva za magisterije i doktorate Medicinskog fakulteta u Splitu
 Predsjednik Povjerenstva za izradu specijalističkog plana i programa
specijalizacije iz onkologije
 Predsjednik Hrvatskog onkološkog društva
 Predsjednik Hrvatskog društva za promicanje kliničkih istraživanja u onkologiji
 Osnivač i prvi predsjednik South Eastern European Research Oncology Group
(kooperativna istraživačka udruga sa slijedećim članicama: Poljska, Slovačka,
Mađarska, Rumunjska, Bugarska, BiH, Turska, Hrvatska)
 Suorganizator US-Croatian Task Force in Oncology (radna skupina sačinjena od
prominantnih članova Nacionalnog instituta za rak SAD i hrvatskih onkologa s
ciljem unaprijeđenja onkološke situacije u Hrvatskoj; izrada Deklaracije protiv
raka, Plana i programa protiv raka, pokretanja kliničkih studija faze II i III
 Advisory Board: Hoffman La-Roche, Novartis, Pfizer, Teva

Publicirani radovi u Current Contenst časopisima:

1. Cvitanović S, Grbić D, Zekan Lj, Boban M., Vrdoljak E, Parpura V, Petrović S,

Marušić M. Hypersensitivity to P. Officinalis pollen: Correlation of IgE with skin
testing methods. Allergol et Immunopathol 1989:17;4:197-200.

2. Cvitanović S, Marušić M, Juričić M, Vrdoljak E, Petrovečki M, Rozga A,

Stavljenić-Rukavina A. Hypersensitivity to Parietaria Officinalis pollen in the
newcomers to the area with the plant. Allergy 1993:48;592-597.

3. Bill CA, Grochan BM, Vrdoljak E, Mendoza EA, Tofilon P. Decreased repair of
radiation-induced DNA double-strand breaks with cellular differentation. Rad Res
1992:132;254-258.

4. Vrdoljak E, Bill CA, Stephens LC, van der Kogel AJ, Kian Ang K, Tofilon PJ.
Radiation induced apoptosis of oligodendrocytes in vitro. Int J Radiat Biol
1992:62;4;475-480.

5. Bill CA, Mendoza E, Vrdoljak E, Tofilon PJ. Enhancment of tumor cell killing in
vitro by pre- and post-irradiation expossure to aclacinomycin A. Radiotherapy
and Oncol 1993:28;63-69.
6. Vrdoljak E, Miše K, Rozga A, Sapunar D, Marušić M. Survival analysis of
untreated patients with non-small lung cancer. Chest 1994;106:1797-81.

7. Sapunar D, Bego K, Pintarić I, Vrdoljak E, Petri N, Saraga-Babić M. Effect of

maternal hyperoxygenation on the experimentally produced uteroplacental
insufficiency in rat. Reprod Fertil Dev 1996:8;379-381.

3
8. Vrdoljak E, Bill CA, Stepens LC, Borchardt PE, Tofilon PJ. Influence of X-rays on
early response gene expression in rat astrocytes and brain tumor cell lines. Int J
Radiat Biol. 1994:66;6:739-747.

9. Vrdoljak E, Miše K, Sapunar D, Rozga A, Marušić M. Staging of untreated

patients with small cell lung cancer. Neoplasma 2001;48:155-157.

10. Phan TP, Crane CH, Janjan NA, Vrdoljak E, Milas L, Mason KA. WR-2721
Reduces Intestinal Toxicity from Concurrent Gemcitabine and Radiation
Treatment. Int J of Pancreatol 2001;29:45-50

11. Vrdoljak E, Hamm W, Omrčen T, Prskalo T. Long lasting complete remission of

a patient with cervical cancer FIGO IVB treated by concomitant
chemobrachyradiotherapy with ifosfamide and cisplatin and consolidation
chemotherapy – A case report. European Journal of Gynacelogical Oncology.
2004;25:247-249.

12. Vrdoljak E, Prskalo T, Frleta Ilić N, Omrčen T, Janković S, Hamm W.

Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed
by consolidation chemotherapy in locally advanced squamous cell carcinoma
(LASCC) of the cervix uteri – Results of a phase II study. International Journal
of Radiation Biology Oncology Physics 2005;61:824-829.

13. Vrdoljak E, Hamm W. Current state-of-the-art of concomitant chemoradiation

in cervical carcinomas. European Journal of Gynacelogical Oncology
2003;26:475-481.

14. Kristensen GB. Vergote I. Stuart G. Del Campo JM. Kaern J. Lopez AB.
Eisenhauer E. Aavall-Lundquist E. Ridderheim M. Havsteen H. Mirza MR.
Scheistroen M. Vrdoljak E. First-line treatment of ovarian cancer FIGO stages
IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin.
International Journal of Gynecological Cancer. 13(Suppl 2):172-177, 2003 Nov-
Dec.

15. Vrdoljak E, Boraska Jelavić T, Saratlija Novaković Ž, Hamm W. Concomitant

Chemobrachyradiotherapy with Ifosfamide and Cisplatin Followed by
Consolidation Chemotherapy in the Treatment of Locally Advanced
Adenocarcinomas or Adenosquamous Carcinomas of the Cervix Uteri. European
Journal of Gynacelogical Oncology 2005;6:602-604.

16. Grubišić Čabo F, Vrdoljak E. Drug-induced hepatitis in a patient with malignant

melanoma treated with interferon alfa 2b adjuvantly whom had been
administered gemfibrozil in therapy. Med Oncol. 2006;23(1):121-4.

17. Čufer T, Vrdoljak E., Gaafar R, Ernesoy I, Pemberton K. Results from a phase
II, open-label, randomized study (SIGN) comparing gefitinib (iressa) with
docetaxel as second-line therapy in patients with advanced (stage IIIb or IV)
non-small-cell lung cancer. Anticancer Drugs, 2006 Apr;17(4):401-9.

18. Vrdoljak E, Boban M, Saratlija-Novakovic Z, Jovic J. Long-lasting partial

regression of a patient with glioblastoma multiforme achieved using edotecarin –
a case report, Croat Med J. 2006 Apr;47(2):305-9.

4
19. Boraska Jelavić T, Barišić M, Drmić I, Boraska V, Vrdoljak E, Peruzović M, Hozo
I, Puljiz Z, Terzić J. Microsatelite GT polymorphism in the toll-like receptor 2 is
associated with colorectal cancer. Clin Genet 2006;70:156-60.

20. Vrdoljak E, Omrčen T, Saratlija Novakovic Z, Boraska Jelavic T, Prskalo T,

Hrepic D, Hamm W. Concomitant chemobrachyradiotherapy with ifosfamide and
cisplatin followed by consolidation chemotherapy: An innovative, very promising
treatment for women with locally advanced carcionoma of the uterine cervix –
final results of a large, prospecitive phase II-study, Gynecology Oncology,
Gynecol Oncol. 2006 Nov;103(2):494-9.

21. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cowthorn JS,
Patel A, Snowdon C, Hall E, Bliss JM, Coombes CR. Skeletal effects of
exemestane on bone-mineral density, bone biomarkers, and fracture incidence
in postmenopausal women with early breast cancer participating in the
Intergroup Exemestane Study (IES): a randomized controlled study.
HTTP://oncology.thelencet.com. Objavljeno online 26.01.2007. Lancet Oncol.
2007 Feb;8(2):119-27.

22. Ortmann O, Albanell J, Cufer T, Dixon MJ, Maass N, Marchetti M, Muñoz M,

Pagani M, Pronzato P, Semiglazov V, Spano JP, Vrdoljak E, Wildiers H.
Adjuvant endocrine therapy for perimenopausal women with early breast
cancer, Breast. 2009 Feb; 18(1):2-7. Epub 2008 Nov 26

23. Vrdoljak E, Miše Petrić B, Lukić B, Curić Z, Bošković L, Tica I. Long-Lasting

Control of Triple-Negative Metastatic Breast Cancer with the Novel Drug
Combination Ixabepilone and Capecitabine - Case Report
Onkologie 2010;33:53-56

24. Librenjak D, Šitum M, Vrdoljak E, Milostić K, Gotovac J. Results of long-term

follow-up of patients with superficial bladder carcinoma treated with
intravesically applied Bacillus Calmette-Guerin vaccine according to the
schedule of 6 weekly + 6 monthly instillations. Uro Onc accepted for publication

25. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Ventilari Da

Costa SC, Ro J, Rubio G, Rondin Manga G, Peck R, Poulart V, Conte P.
Randomized Phase III trial of Ixabepilone Plus Capecitabine vs Capecitabine in
patients with metastatic breast cancer (MBC) previously treated with an
anthracycline and a taxane. JCO 2010;28:3256-63

26. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A,
Bliss JM, Coombes RC, Kilburn LS. Reversal of skeletal effects of endocrine
treatments in the Intergroup Exemestan Study. Breast Cancer Res Treat 2010.

27. Librenjak D, Šitum M, Vrdoljak E, Milostić K, Gotovac J. Results of long-term

follow-up of patients with superficial bladder carcinoma treated with
intravesically applied Bacillus Calmette-Guerin vaccine according to the
schedule of 6 weekly + 6 monthly instillations. Urologic Oncology: Seminars and
Original Investigations, 2010;

5
 28. Vrdoljak E, Omrčen T, Boban M, Hrabar A. Phase II stud< of bevacizumab in
combination with capecitabine as first-line treatment in eldery patients with
metastatic colorectal cancer. Anticancer Drugs, 2011;22:191-197.

29. Vrdoljak E, Boban M, Omrcen T, Hrepic D, Vidas Fridl V, Boskovic L.

Combination of capecitabine and mitomycin C as first line treatment in patients
with metastatic breast cancer. Neoplasma, 2011;58:172-178.

30. Gianni L, Dafni U, Gelber RD, Azambuja E, Meuhlbauer S, Goldrisch A, Untch

A, Smith J, Besalga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A,
Mediola C, Pulzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z,
Skiadopulous G, Procter M, Pritchard KI, Piccart Gebhart MJ, Bell R. Tretment
with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER-2
positive early breast cancer: a 4-year follw-up of a randomized controlled trial.
Lancet Oncology 2011;12:236-244

31. Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J,

Todorovic V, Borojevic N, Croitoru A. Cancer epidemiology in Central, South
and Eastern European countries, Croat Med J. 2011 Aug 15;52(4):478-87.
.

Publicirani radovi u Excerpta Medica časopisima:

1. Cvitanović S, Grbić D, Zekan Lj, Petrović S, Vrdoljak E, Parpura V, Boban M.

Ketotifen and nasal steroid in hay fever pollinosis. Res Disease 1989:41;205-
208.

2. Tofilon P, Vrdoljak E, Kian Ang K. Investigation of central nervous system

radiobyology using glial cell cultures. Cancer Bull 1992:44;92-97.

3. Vrdoljak E, Milas L. Apoptosis: Basic biology and relationship to cancer. CMJ

1996:37;141-151.

4. Krolo M, Vilović K, Sapunar D, Vrdoljak E, Saraga-Babić M. Fibronectin

Expression in the developing human spinal cord, nerves and ganglia. CMJ
1998:39;386-391.

5. Vrdoljak E. Chemotherapy and Radiotherapy of Colon and Rectal Carcinoma.

Libri Oncologici 2001;29:30-40.

6. Vrdoljak E, Glavina Durdov M, Kuzmić Prusac I, Tomić S, Rozga A, Petrić Miše

B, Alfirević D, Bezić J, Forenpoher G, Karaman I, Pešutić Pisac V, Rakanović S.
Correlation between standard IHC method and HercepTest in detection of
HER2/neu overexpression in breast cancer. Libri Oncologici 2001;29:8-12.

7. Krznarić Ž, Juretić A, Šamija M, Dobrila Dintinjana R, Vrdoljak E, Samaržija M,

Kolaček S, Vrbanec D, Prgomet D, Ivkić M, Zelić M. Hrvatske smjernice za
primjenu eikozapentaenske kiseline I megestrol acetata u sindromu tumorske
kaheksije. Liječ Vjesn 2007;129:381-386.

6
 8. Vrdoljak E, Omrčen T, Boban M. Capecitabine and mitomycin-C in therapy of
pretreated patients with metastatic colorectal cancer: single center retrospective
study with 36 patients, J BOUN. 2008 Oct-Dec; 13(4):513-8.

9. E. Vrdoljak, M. Boban, M. Ban. Lapatinib in the treatment of HER-2

overexpressing breast cancer. Journal of BUON 16:393-399, 2011

Publicirani radovi u ostalim časopisima:

1. Vrdoljak E, Omrčen T, Mikuš S, Petrić-Miše B. Karcinom jajnika. Medicus,

2001;10:207-211.

2. Vrdoljak E. Boban M, Ilić-Frleta N. Suvremeni pristup liječenju karcinoma

vrata maternice. Medicus, 2001;10:211-214.

Sudjelovanje u pisanju medicinskih knjiga:

1. J. Bilić, E. Vrdoljak. Probavni sustav, u Radioterapija, ur. M. Šamija, Z. Krajina i

A. Purišić, Nakladni Zavod Globus, Zagreb, 1996, 263-275.

2. J. Bilić, E. Vrdoljak. Radioterapija tumora probavnog sustava, u Radioterapija

gdje-kada-kako, ur. M. Šamija, Z. Krajina i I. Voskrsenski, Medicinski Fakultet
Sveučilišta u Zagrebu, Katma, Zagreb, 1993, 44-50.

3. E. Vrdoljak. Tumori jetre, u Odabrana poglavlja iz gastroenterologije, ur. I. Hozo i

S. Miše, DES, Split, 1999, 303-313.

4. E. Vrdoljak. Konkomitantna kemoradioterapija, u Internistička onkologija, Z.

Mršić Krmpotić, Anton Roth i suradnici, Medicinska naklada, Zagreb 2004.

5. E. Vrdoljak, D. Hrepić, Dijagnostičke metode i terapijski uređaji u onkologiji, u

Janković, Eterović i suradnici Fizikalne osnove i klinički aspekti slikovne
dijagnostike, Medicinska naklada, Zagreb, 2002, 127-136.

6. M. Samija, E. Vrdoljak, Z. Krajina. Klinička Onkologija. Medicinska naklada,

Zagreb, 2006.

7. E. Vrdoljak, M. Ban. Malingnancies and intensive care medicine

Publicirani radovi u zbornicima skupova:

1. Vrdoljak E, Bill CA, Stephens LC, Tofilon PJ. Modulation of gene expression in
astrocytes by ionizing radiation. Abstracts of Papers for the Fortieth Annual
Meeting of the Radiation Research Society; 1992:119.

2. Vrdoljak E, Bill CA, Tofilon PJ. X-ray induced early response gene expression in
rat astrocytes and brain tumor cell lines. Congress Proceedings, Tenth
International Congress of Radiation Research, 1995:223.

7
3. Bill CA, Grochan BM, Vrdoljak E, Tofilon PJ. Reduction of radiation-induced
DNA double-strand break repair with cellular differentation. Abstracts of Papaers
for the Fortieth Annual Meeting of the Radiation Research Society, 1992:75.

4. Vrdoljak E, Prskalo T, Frleta-Ilić N, Snaller V, Janković S. Study of potential role

of ifosfamide in conjuction with cisplatin in the concomitant chemoradiotherypy
treatment of locally advanced carcinoma of the cervix. Proc ASCO
2001;20:178b.

5. Vrdoljak E, Prskalo T, Frleta Ilić N, Hrepić D. Studija o potencijalnoj ulozi

ifosfamida u kombinaciji s cisplatinom u liječenju lokalno uznapredovalog
inoperabilnog raka vrata maternice. Knjiga sažetaka HDRO 2001;43.

6. Vrdoljak E. Preliminarni rezultati ankete u centralnoj i istočnoj Europi o liječenju

karcinoma ovarija i analiza situacije u Hrvatskoj. Zbornik radova I Kongresa
Hrvatskog onkološkog društva. 2001; 96.

7. Hamm W, Vrdoljak E. Simultane Chemo-Brachyradiotherapie mit

Ifosfamid(I)/Cisplatin(P) beim Zervixkarzinom FIGO IB2-IVA. Archives of
Gynecology and Obstetrics 2002;267:S37.

8. Vrdoljak E, Prskalo T, Frleta Ilić N, Hamm W. Concomitant

chemobrachyradiotherapy with ifosfamide and cisplatin followed by
consolidation chemotherapy in locally advanced squamous cell carcinoma of the
cervix uteri. Proc ASCO 2002;21:873.

9. Vrdoljak E. Uloga kapecitabina u liječenju raka dojke. Zbornik radova 12.

Znanstvenog sastanka o bolestima dojke. 2002; 25-29.

10. Vrdoljak E, T. Omrčen, T. Prskalo, N Frleta Ilić, M. Boban, B. Petrić Miše, T.

Boraska, K. Šitum, D. Hrepić, S. Janković, W. Hamm. Konkomitantna
kemoradioterapija u liječenju raka vrata maternice – mogućnost daljnjeg
unapređenja liječenja. Knjiga sažetaka. HDRO 2003; 16.

11. Vrdoljak E. Konkomitantna kemobrahiradioterapija s ifosfamidom i cisplatinom

praćena konsolidacijskom kemoterapijom u liječenju lokalno uznapredovalog
planocelularnog karcinoma vrata maternice – rezultati studije faze II. Knjiga
sažetaka. HDRO 2003; 17.

12. Vrdoljak E, Prskalo T, Frleta Ilić N, Hamm W. Concomitant

chemobrachyradiotherapy with ifosfamide and cisplatin followed by
consolidation chemotherapy in locally advanced squamous cell carcinoma:
Results of the phase II study. Proc of Society of Gynacelogic Oncologist
2003:79.

13. Vrdoljak E. Omrčen T, Prskalo T, Frleta Ilić N, Boban M, Petric Mise B, Boraska
Jelavić T, Šitum K, Hrepić D, Janković S, Hamm W. Konkomitantna
radiobrahiradiokemoterapija u liječenju raka vrata maternice – mogućnost
daljnjeg unapređenja liječenja. Kniga sažetaka, HDRO 2003; 26.

8
14. E. Vrdoljak, F. Grubišić Čabo. Optimalna integracija kemoterapije i hormonske
terapije u adjuvantnom liječenju raka dojke. Zbornik radova 14. Znanstvenog
sastanka o bolestima dojke. 2004; 131-138.

15. Vrdoljak E, Boraska Jelavić T. Uloga hormonske terapije u liječenju raka dojke.
Zbornik radova II Kongresa Hrvatskog onkološkog društva. 2004; 54.

16. Čufer T, Vrdoljak E. Results from a phase II, open-label, randomized study
(SIGN) comparing gefitinib with docetaxel as second line therapy in patients with
advanced (stage IIIb and IV) non-small-cell lung cancer. ASCO Annual Meeting
Proceedings 2005:7035.

17. Čufer T, Vrdoljak E. SIGN: a Phase II, open label, randomized study comparing
gefitanib (Iressa) with docetaxel as second-line therapy in patients with
advanced (stage IIIb or IV) non-small-cell lung cancer. Abstracts of the 11th
World Conference on Lung Cancer, Lung Cancer 2005;49, S87.

18. Vrdoljak E. Are we ready for aromatase inhibitors in adjuvant setting?

European School of Oncology, 3rd Sarajevo Breast Cancer Conference,
Abstract book; 2005, 197-198.

19. Vrdoljak E. The role of the endocrine therapy in breast cancer. European
School of Oncology, 2nd Sarajevo Breast Cancer Conference, Abstract book
2003.

20. Vrdoljak E. Hormonal therapy of breast cancer. Evidence Based Management

of Breast Cancer. European School of Oncology, Abstract book 2001.

21. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Porter LS, Snowdon CF,
Hall E, Bliss JM, Coombes RC. Skeletal effect of exemestane in the Intergroup
Exemestane Study (IES) – 2 year bone mineral density (BMD) and bone mineral
data. Breast Cancer 2005;94:5076.

22. Vrdoljak E., Curić Z, Boraska Jelavić T, Novaković Saratlija Ž, Boban M. Uloga
aromataznih inhibitora u liječenju raka dojke – da li su svi aromatazni inhibitori
jednaki?. Zbornik radova 15. Znanstvenog sastanka o bolestima dojke. 2005;
137-157.

23. Vrdoljak E., Šitum K. Neoadjuvantno sustavno liječenje raka dojke – današnje
stanje i buduće perspektive. Zbornik radova 16. Znanstvenog sastanka o
bolestima dojke. 2006; 157-177.

24. Vrdoljak E. Omrčen T, Saratlija Novaković Ž, Borsaka Jelavić T, Prskalo T,

Hrepić D, Hamm W. Konkomitantna kemobrahiradioterapija s ifosfamidom i
cisplatinom praćena konsolidacijskom kemoterapijom: Inovativan i obećavajući
način liječenja žena s lokalno uznapredovalim karcinomom vrata maternice –
rezultati prospektivne studije faze II. Kniga sažetaka, HOK 2006; 41.

25. Cufer T, Vrdoljak E. Results from a phase II, open label, randomized study
(SIGN) comparing gefitanib with docetaxel as second line therapy in patients
with advanced (stage IIIb or IV) non small cell cancer. Proc ASCO 2005;23:16S.

9
26. Vrdoljak E., Petrić Miše B. Protokol za adjuvantno sustavno liječenje raka dojke
u vrlo mladih žena. Zbornik radova 17. Znanstvenog sastanka o bolestima
dojke. 2007; 225-238.

27. Vrdoljak E, Omrčen T., Novosti u kemoterapijskom liječenju raka prostate.

Knjiga sažetaka, 3 Hrvatski urološki kongres, 2005; 92.

28. Omrčen T, Vrdoljak E, Primarna radiokemoterapija raka mokraćnog mjehura, 3

Hrvatski urološki kongres, 2005; 86

29. Hortobagyi GN, Perez E, Vrdoljak E, Medina C, Xu B, Sparano P. Analysis of

overall survival among patiants with mBC receiving either ixabepilone plus
capacitabine or capecitabine alone – phase III trial. Proc ASCO Breast, Abst.
186.

30. Vrdoljak E, Wojtukijewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J,

Beslia S, Todorovic V, Borojevic N, Yilmaz U. Current oncology situation in
eastern and southern European countries: South Eastern European Research
Oncology Group (SEEROG) initiative. Annals of Oncology, 2008:716P.

31. Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Cawthorn S, Patel A,
Coombes C, Bliss JM, Kilburn LS. Reversal of skeletal effects of endocrine
treatments in the intergroup exemestane study. Breast Cancer 2008;Abstract No
1128.

32. Roche H, Li R, Ro J, Vrdoljak E, Rahman ZU, Medina C, Conte P, Volles LA,

Poulart V, Sparano JA. Ixabepilone plus capecitabine improves progression free
survival in patients with metastatic breast cancer resistant to taxanes: a pooled
analysis form two phase III trials. Breast Cancer 2008;Abstract No 2015.

33. Perez E, Pivot X, Vrdoljak E, Sparano JA, Vogel C, Peck R, Mukhopadhyay P,

Vahdat L. A prospective characterization of the resolution of ixabepilone induced
peripheral neuropathy: dana from a large registrational program in patients with
metastatic breast cancer. Breast Cancer 2008;Abstract No 6140.

34. Vrdoljak E, Curić Z. Adjuvantna kemoterapija raka dojke 2008: dostignuća i

perspektive. Zbornik radova 18. Znanstvenog sastanka o bolestima dojke. 2008;
185-202.

35. Vrdoljak E, Berić Jozić G, Bošković L, Ban M. Suvremeno sustavno i lokalno

liječenje metastatskog raka dojke. Zbornik radova 19. Znanstvenog sastanka o
bolestima dojke. 2009; 65-91.

36. Vrdoljak E, Omrcen T, Hrabar A. Phase II study of bevacizumab in combination

with capecitabine as first line treatment in elderly patients with metastatic
colorectal cancer (MCC), 2009 ASCO Annual Meeting, Abstract No e15074

37. Vrdoljak E, Radiotherapy in lung cancer, Lung Cancer and Mesothelioma, 17 –

18 June 2010, Golnik, Slovenia, European School of Oncology

10
 38. Vrdoljak E, Berić Jozić G, Bošković L, Ban M. Perspektive sustavnog liječenja
raka dojke – individualizirana ciljana terapija. Zbornik radova 20. Znanstvenog
sastanka o bolestima dojke. 2010;35-48.

39. Vrdoljak E, Boban M, Omrcen T, Hrepic D, Fridl-Vidas V, Boskovic L.

Combination of capecitabine and mitomycin C as first-line treatment in patients
with metastatic breast cancer, Neoplasma 58, 2,2011 (172:178)

40. L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L.D. Bosserman, J. A.

Sparano, J. Baselga, P. mukhopadhyay, V. Valero, Efficacy and safety if
ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-
pretreated metastatic breast cancer (Abstract #1083), ASCO Annual Meeting,
Abstract No e11588

41. Šundov Ž, Kunac N, tomić S, Čaškun V, Kalebić M, Družijanić N, Vrdoljak E.

Koekspresija COX-2 i MMP-2 u karcinomima debelog crijeva kliničkog stadija
Dukes B i njihova povezanost s gustoćom novostvorenih limfnih (LVD) i krvnih
žila (MVD). Simpozij Hrvatskog onkološkog društva o tumorima probavnog
trakta. Knjiga sažetaka 2011; 42s

42. E. Vrdoljak, M. Ban. Jesu li nam potrebni centri za rak dojke kao središta
izvrsnosti za dijagnostiku i liječenje. Zbornik radova 21. Znanstvenog sastanka o
bolestima dojke. 2011;43-51.

43. E. Vrdoljak, J. Viculin. Moderni pristup u liječenju sindroma zloćudnog umora kod
onkoloških bolensika. Knjiga sažetaka IV. hrvatskog kongresa Potporno liječenje
onkoloških bolesnika; 2011; 16:18

Mentorstvo na doktorskim disertacijama:

1. Dr. sc. Tihana Boraska Jelavić “Konkomitanta kemobrahiradioterapija

ifosfamidom i cisplatinom praćena konsolidacijskom kemoterapijom u liječenju
lokalno uznapredovalog raka vrata maternice”

2. Dr. Tomislav Omrčen “Bevacizumab u kombinaciji s kapecitabinom u liječenju

starijih bolesnika s metastatskim rakom debelog crijeva – studija faze II”

3. Dr. Marijo Boban „Kombinacija Kapecitabina i Mitomicina kao prvolinijska terapija

bolesnica s metastatskim rakom dojke – klinička studija faze II“

Organizacija tečajeva:

11
 1. Inicijator i tajnik organizacije tečaja trajne izobrazbe liječnika primarne
zdravstvene zaštite iz područja onkologije. Isti je održan 1994. godine s velikim
uspjehom. Prijavljeno je bilo 105 liječnika.

2. Kongres Hrvatskog društva za onkologiju i radioterapiju, član organizacijskog

odbora, Plitvice, 07-10.06.2001.

3. Kongres Hrvatskog onkološkog društva, član organizacijskog odbora, Zagreb

28-30.11.2001

4. Clinical oncology in Croatia – strategic planinning and beyond, član

organizacijskog odbora (lipanj, 2007)

Sudjelovanje u tečajevima dobre kliničke prakse u provođenju kliničkih

istraživanja:

1. Lung Cacer Workshop in Zagreb, Croatia, 19.-21.lipnja 2008.

Inicirane i pokrenute vlastite kliničke studije:

1. Konkomitanta kemobrahiradioterapija uifosfamidom i cisplatinom praćenja

konsolidacijskom kemoterapijom u liječenju lokalno uznapredovalog raka vrata
maternice

2. Bevacizumab u kombinaciji s kapecitabinom u liječenju starijih bolesnika s

metastatskim rakom debelog crijeva – studija faze II

3. Protokol MO 18646 Klinička studija faze II o prvolinijskom liječenju bolesnica s

metastatskim rakom dojke kombinacijim mitomicina i kapecitabina

Sudjelovanje u provođenju multicentričnih kliničkih studija:

1. Phase III study of doxorubicin plus Taxol (pacitaxel) combination versus 5-

fluorouracil plus doxorubicin plus cyclophosphamide combination as a first line
treatment for patients with metastatic breast cancer. BMS sponsored trial

2. A multicenter, multinational, open-label, single group, single and multiple dose

study of Foscan-mediated photodynamic therapy (PDT) for the paliative
treatmnet of recurrent, refractory or second primary squmous cell carcinomaas
of the head and neck in patients considered to be incurable with surgery or
radiotherapy. Scotia pharmaceuticals sponsored trial.

3. A double blind, placebo controled, randomised, parallel group, multicentre

phase II dose response study of EPA 95% diester capsules in patients with
cancer cachexia. Scotia pharmaceuticals sponsored trial.

12
4. Evaluation of clinical efficacy of TTS-fentanyl in strong opioid naive and strong
opioid pre-treated adult patients with cancer releated pain without stabilization
phase: An open multicentre study. Janssen Cillag sponsored trial.

5. An open-label, randomized, phase III study comparing Xeloda (capacitabine)

with i.v. bolus 5-fluorouracil in combination with low dose leucovorin as adjuvant
chemotherapy in patients who underwent surgery for Dukes C colon cancer.
Hoffman La Roche sponsored trial.

6. A randomized trial of paclitaxel/epirubicin/carboplatin combination (TEC) versus

paclitaxel/carboplatin (TC) in the treatment of women with advanced ovarian
cancer. An Intergroup trial (NSGO, EORTC and NCIC CTG)

7. Randomised double blind trial in postmenopausal women with primary breast

cancer who have received adjuvant tamoxifen for 2-3 years, comparing
subsequent adjuvant exemestan treatment with further tamoxifen. Pharmacia
Upjohn sponsored trial.

8. A phase III, randomized, open-label, multicenter, international study comparing

the combination of SU5416/Irinotecan/ 5-Fluorouracil/Leucovorin versus
Irinotecan/5-Fluorouracil/Leucovorin alone as first-line therapy of patients with
previously untreated metastatic colorectal cancer

9. A multicenter phase III randomized trial comparing docetaxel in combination with

doxorubicin and cyclophosphamide (TCA) versus doxorubicine and
cyclophosphamide followed by docetaxel (AC – T) as adjuvant treatment of
operable breast cancer HER2neu negative patients with positive axillary lymph
nodes

10. A multicenter phase III randomized trial comparing doxorubicin and

cyclophosphamide followed by docetaxel (AC – T) with doxorubicin and
cyclophosphamide followed by docetaxel and transtuzimab (AC-TH) and with
docetaxel, platinum salt and transtuzimab (TCH) in the treatment of node
positive and high risk node negative patients with operable breast cancer
containing the HER2neu alteration

11. A randomised three-arm multi-centre comparison of 1 year and 2 years of

Herceptin versus no Herceptin in women with HER2-positive primary breast
cancer who have completed adjuvant chemotherapy, Protocol BO 16348/BIG
01-01

12. A phase II study of first line weekly Taxol plus herceptin followed by weekly
herceptin in women with locally advanced or metastatic breast cancer and
HER2 overexpression

13. A phase II, Open Label, Randomized, Comparative Study of Exemastan versus
Anastrazole in Post-menopausal Breast Cancer Subjects with Visceral Disease

14. A phase II, open-label, randomised, parallel group, non-comparative study of

ZD1839 (Iressatm) and Docetaxel (Taxotere®) as second-line therapy in subjects
with advanced (stage IIIb or IV) non-small cell lung cancer

13
15. A phase III, randomized, open-label study of IV Edotecarin vs Temozolomide or
Carmustine (BCNU) or Lomustine (CCNU) in patients with glioblastoma
multiforme that has progressed/recurred after alkylator-based (neo)adjuvant
chemotherapy

16. A phase II multicenter, randomized, double-blind, placebo controlled, dose

ranging, parallel group study of the efficacy and safety of GW597599 when
administrated as 2.5 mg, 7.5 mg, 15 mg, and 25 mg oral tablets in combination
with ondasetron hydrocloride and dexamethasone for the prevention of
chemotherapy induced nausea and vomiting in cancer subjects receiving highly
emetogenic cisplatin-based chemotherapy.

17. Cardiac safety of recombinant humanized anti-p185 HER2monocional antibody

trastuzumab (Herceptin) in combination with epirubicin / cyclophosphamide as
first line therapy in anthracycline-naïve patients with HER2/neu overexpressing
metastatic breast cancer

18. A multicenter phase III randomised trial comparing Docetaxel (Taxotere) and
Trastuzumab (Herceptin) with Docetaxel (Taxotere), Carboplatin and
Trastuzumab (Herceptin) as first line chemotherapy for patients with advanced
breast cancer containing HER2 gene amplification.

19. Open-label Trial of Glivec in Patients with Unresectable or Metastatic Malignant

Gastrointestinal Stromal Tumors Expressing c-kit.

20. A multicenter phase III randomized trial comparing Docetaxel (Taxotere) and
Trastuzumab (Herceptin) with Docetaxel (Taxotere), Carboplatin and
Trastuzumab (Herceptin) as first line chemotherapy for patient with advanced
breast cancer containing HER2 gene amplification.

21. A Multi-Center, Multi-National, Double-Blind, Randomized Phase III Study Of

Satraplatin Plus Prednisone Or Placebo Plus Prednisone In Patients With
Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic
Chemotherapy Regimen

22. An open-label randomized phase III study of intermittent oral capecitabine in

combination with intravenous oxaliplatin (Q3W) (XELOX) versus bolud and
continuous infusion fluorouracil/intravenous leucovorin with intravenous
oxaliplatin (Q“W) (FOLFOX-4) as treatment for patients with metastatic
colorectal cancer who have received prior treatment with CPT-11 in combination
with 5-FU/LV as first-line therapy

23. A randomized, double-blind, placebo controlled, multicenter phase III study

comparing GW 572016 and letrozole versus letrozole in subjects with
estrogen/progesteron receptor positive advanced or metastatic breast cnacer,
EGF 30008

24. A Phase III Trial Of Novel Epothilone BMS-247550 Plus Capecitabine Versus
Capecitabine Alone In Patients With Advanced Breast Cancer Previously
Treated With An Anthracycline And A Taxane

14
 25. A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of
E7389 versus “Treatment of Physician's Choice” in Patients with Locally
Recurrent or Metastatic Breast Cancer, Previously Treated with At Least Two
and Maximum of Five Prior Chemotherapy Regiments, Including an
Anthracycline and a Taxane

26. A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant

Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer

27. A SU011248 Expanded Access Protocol for Therapy of Patients with Metastatic
Renal Cell Carcinoma who are Ineligible for Participation in other SU011248
Protocols but may Derive Benefit from Treatment with SU011248

28. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with
HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer
Comparing Chemoterapy Plus Trastuzumab with Chemoterapy Plus
Trastuzumab Plus Bevacizumab

29. A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best

Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Following
Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing
Combination Therapy

30. A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advanced or

Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Split, Prof.dr.sc. Eduard Vrdoljak

15